~~<i id='FCF420D84F'><strike id='FCF420D84F'><tt id='FCF420D84F'><pre id='FCF420D84F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：Wikipedia 2025-09-28 16:34:45 - browse：7285

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Why health workers in Gaza are injured or die at high rates

focus

entertainment

focus

leisure time

MathieuLewis-Rolland/GettyImagesNEWORLEANS—TheannualmeetingoftheAmericanSocietyofReproductiveMedicin

WSS

STAT Summit: Biotech founders on deal

CEOs share strategies for surviving biotech slump

Solve the antibiotic resistance crisis with preventive drugs

STAT Summit: GSK CEO on pharma giant's new direction

Pharmacists can make shortage drugs, but at what cost?

The explosion of genetic testing requires a new approach

knowledge

fashion

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA gives detailed accounting of AI

Heart attack and stroke risk calculators need revising

Hospital price transparency does save money, advocate argues

Peter Hotez and the public health issue of online harassment

First Opinion Podcast: Long Covid needs a new approach

Guidelines to prevent youth baseball injuries need more muscle

FDA gives detailed accounting of AI

Bright Health sells Medicare Advantage business to Molina

Eli Lilly expects to double planned employment in Boston center

entertainment

Hospital price transparency does save money, advocate argues

FDA warns J&J's Abiomed: We will regulate your software

Medicare reduced heart disease by changing how it pays doctors

STAT Summit: How a Chicago ER doctor tackles gun violence

Medicare reduced heart disease by changing how it pays doctors

FDA gives detailed accounting of AI

entertainment

focus

focus

leisure time